Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer

被引：1
|
作者：
Takeda, Masayuki [1 ]
Watanabe, Satomi [1 ]
Rothenberg, S. Michael [2 ]
Kherani, Jennifer [2 ]
French, Pearl P. [3 ]
Olek, Elizabeth [2 ]
机构：
[1] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[2] Loxo Oncol Inc, Stamford, CT USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5236
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer
    Watanabe, Satomi
    Takeda, Masayuki
    Otani, Tomoyuki
    Yoshida, Takeshi
    Sakai, Kazuko
    Olek, Elizabeth
    Rothenberg, S. Michael
    Kherani, Jennifer
    French, Pearl P.
    Nishio, Kazuto
    Ito, Akihiko
    Nakagawa, Kazuhiko
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 103 - 106
  • [2] Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid
    Kander, Elizabeth M.
    Shah, Manisha H.
    Zhou, Ye
    Goyal, Ashima
    Palmer, Joshua D.
    Owen, Dwight H.
    Shilo, Konstantin
    Patel, Gopal
    Raval, Raju R.
    Gonzalez, Javier
    Nguyen, Michele
    Olek, Elizabeth
    Kherani, Jennifer
    Rothenberg, S. Michael
    Konda, Bhavana
    [J]. CLINICAL LUNG CANCER, 2021, 22 (03) : E442 - E445
  • [3] Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
    Loong, H.
    Goto, K.
    Park, K.
    Ohe, Y.
    Nishio, M.
    Cho, B. C.
    Kim, Y. J.
    French, P.
    Soldatenkova, V.
    Tan, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S231 - S232
  • [4] Response to Selective ET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
    Guo, Robin
    Schreyer, Mark
    Chang, Jason C.
    Rothenberg, S. Michael
    Henry, Dahlia
    Cotzia, Paolo
    Kris, Mark G.
    Rekhtman, Natasha
    Young, Robert J.
    Hyman, David M.
    Drilon, Alexander
    [J]. JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 6
  • [5] LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases
    Velcheti, V.
    Bauer, T.
    Subbiah, V.
    Cabanillas, M.
    Lakhani, N.
    Wirth, L.
    Oxnard, G.
    Shah, M.
    Sherman, E.
    Smith, S.
    Eary, T.
    Cruickshank, S.
    Tuch, B.
    Ebata, K.
    Nguyen, M.
    Corsi-Travali, S.
    Rothenberg, S.
    Drilon, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1778 - S1778
  • [6] Systemic treatment with a RET inhibitor (LOXO-292) in a patient with metastatic colorectal cancer with RET fusion (NCOA4-RET)
    Butt, Sabeeh-ur-Rehman
    Happe, Marlene
    Torga, Gonzalo
    Patrikidou, Anna
    Arkenau, Hendrik-Tobias
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 115 - 116
  • [7] Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
    Ortiz, Michael V.
    Gerdemann, Ulrike
    Raju, Sandya Govinda
    Henry, Dahlia
    Smith, Steve
    Rothenberg, S. Michael
    Cox, Michael C.
    Proust, Stephanie
    Bender, Julia Glade
    Frazier, A. Lindsay
    Anderson, Peter
    Pappo, Alberto S.
    [J]. JCO PRECISION ONCOLOGY, 2020, 4 : 341 - 347
  • [8] Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer
    Wirth, Lori J.
    Sherman, Eric J.
    Robinson, Bruce
    Solomon, Benjamin
    Kang, Hyunseok
    Lorch, Jochen H.
    Worden, Francis
    Brose, Marcia S.
    Leboulleux, Sophie
    Godbert, Yann
    Meurer, Marie
    Morris, John
    Owonikoko, Taofeek K.
    Tan, Daniel Shao-Weng
    Gautschi, Oliver
    Patel, Jyoti
    Yang, Luxi
    Kherani, Jennifer
    Cabanillas, Maria E.
    Shah, Manisha H.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S289 - S289
  • [9] Structural Insight into Sensitivity and Resistance of RET Mutants to Selpercatinib (LOXO-292)
    Shen, T.
    Terzyan, S. S.
    Liu, X.
    Mooers, B. H.
    Wu, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S32 - S33
  • [10] Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion plus Non-Small Cell Lung Cancer
    Oxnard, G.
    Subbiah, V.
    Park, K.
    Bauer, T.
    Wirth, L.
    Velcheti, V.
    Shah, M.
    Besse, B.
    Boni, V.
    Reckamp, K.
    Loong, H.
    Bazhenova, L.
    Solomon, B.
    Tan, D.
    Patel, J.
    Johnson, M.
    Gazzah, A.
    Mok, T.
    Smith, S.
    Tuch, B.
    Ebata, K.
    Zhu, E.
    Nguyen, M.
    Huang, X.
    Cruickshank, S.
    Rothenberg, S.
    Drilon, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S349 - S350
12345